Skip to main content
Clinical Trials/NCT07653126
NCT07653126CompletedNot Applicable

Use of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumour (NET) Patients in Germany - A Retrospective Evaluation in German Centers for NET (LUNET-2 Study)

Novartis Pharmaceuticals7 sites in 1 country117 target enrollmentStarted: April 3, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
117
Locations
7

Study Overview

Brief Summary

The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with a confirmed diagnosis of GEP-NET (any localization of the primary tumor including cancer of unknown primary origin [CUP], any Grade).
  • Patients with a first cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01 July 2020 and 30 June 2021.

Exclusion Criteria

  • Received a combination of PRRT with chemotherapy.
  • Received a combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (7)

Loading locations...

Similar Trials

A Study of Peptide Receptor Radionuclide... | Clinical Trial